Transcriptional activity of potent glucocorticoids: Relevance of glucocorticoid receptor isoforms and drug metabolites

Skin Pharmacology and Applied Skin Physiology

Volumn 16, Issue 3, 2003, Pages 143-150

  Spika, I ^a   Hammer, S ^a   Kleuser, B ^a   Korting, H C ^b   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fibroblasts; Glucocorticoids; Keratinocytes; Prednicarbate; Transactivation

Indexed keywords

BETAMETHASONE VALERATE; DEXAMETHASONE; DRUG METABOLITE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MIFEPRISTONE; PREDNICARBATE; RECEPTOR SUBTYPE;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CELL; TRANSCRIPTION INITIATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE 17-VALERATE; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXAMETHASONE; FIBROBLASTS; HUMANS; IMMUNOBLOTTING; KERATINOCYTES; MALE; MIFEPRISTONE; PREDNISOLONE; RECEPTORS, GLUCOCORTICOID; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 0037247564     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069754     Document Type: Article

References (28)

1. Korting HC, Unholzer A, Schäfer-Korting M, Tausch I, Gassmueller J, Nietsch KH: Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002;15:85-91.
2. Hanifin J, Abrams B, Cherill R: Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a nonhalogenated prednisolone derivative. J Geriatr Dermatol 1994;2:119-127.
3. Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S: Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 1993;54:448-456.
4. Lange K, Gysler A, Bader M, Kleuser B, Korting HC, Schäfer-Korting M: Prednicarbate versus conventional topical glucocorticoids: Pharmacodynamic characterization in vitro. Pharm Res 1997;14:1744-1749.
5. Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schäfer-Korting M: Cutaneous inflammation and proliferation in vitro: Differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol 2000;13:93-103.
6. Barth J, Lehr KH, Derendorf H, Möllmann HW, Höhler T, Hochhaus G: Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. Skin Pharmacol 1993;6:179-186.
7. Gysler A, Lange K, Korting HC, Schäfer-Korting M: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997;14:793-797.
8. Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje HD, Schäfer-Korting M: Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 1999;16:1386-1391.
9. Göttlicher M, Heck S, Herrlich P: Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 1998;76:480-489.
10. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985;318:635-641.
11. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP: Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435-2441.
12. Oakley RH, Sar M, Cidlowski JA: The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996;271:9550-9559.
13. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA: The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 1999;274:27857-27866.
14. Hecht K, Carlstedt-Duke J, Stierna P, Gustafsson J, Bronnegard M, Wikstrom AC: Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. J Biol Chem 1997;272:26659-26664.
15. Hamid QA, Wenzel SE, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte JJ, Chrousos GP, Szefler SJ, Leung DY: Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999;159:1600-1604.
16. Leung DY, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-1574.
17. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH: Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 2000;105:943-950.
18. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y: Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-866.
19. Danielsen M, Northrop JP, Ringold GM: The mouse glucocorticoid receptor: mapping of functional domains by cloning, sequencing and expression of wild-type and mutant receptor proteins. EMBO J 1986;5:2513-2522.
20. Neumann JR, Morency CA, Russian KO: A novel rapid assay for chloramphenicol acetyltransferase. Biotechniques 1987;5:444-447.
21. Ponec M, Kempenaar J, Shroot B, Caron JC: Glucocorticoids: binding affinity and lipophilicity. J Pharm Sci 1986;75:973-975.
22. Pörtner M, Möllmann H, Rohdewald P: Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters. Pharm Res 1988;5:623-627.
23. Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94:557-572.
24. Jaffuel D, Demoly P, Gougat C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M: Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med 2000;162:57-63.
25. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997;11:1245-1255.
26. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM: Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab 1999;84:4055-4061.
27. Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G: Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. Mol Pharmacol 1999;56:797-806.
28. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001;166:1975-1982.